Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Myelofibrosis · Acute Myeloid Leukemia

Karyopharm Therapeutics

Karyopharm Therapeutics Inc

Karyopharm Therapeutics clinical programs — 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
Status
Public
HQ
85 Wells Avenue, Newton, MA 02459, US
Employees
313
Programs
82
Drugs
53
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Karyopharm Therapeutics projects

51 ClinicalTrials.gov programs sponsored by Karyopharm Therapeutics.

Karyopharm Therapeutics has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

51 programs

Clinical programs

Page 1 of 2

  1. Cyclophosphamide

    Karyopharm Therapeutics Inc

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  2. Decitabine

    Karyopharm Therapeutics Inc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  3. Docetaxel

    Karyopharm Therapeutics Inc

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. IST-342

    Karyopharm Therapeutics Inc

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  5. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  6. KCP-330-009

    Karyopharm Therapeutics Inc

    Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

    phase 2 other active

    1 trial

  7. KPT-8602

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule completed

    1 trial

  8. MyDRUG (MMRC-085)

    Karyopharm Therapeutics Inc

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  9. Open Label Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule terminated

    1 trial

  10. Pacritinib

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    Karyopharm Therapeutics Inc

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  12. SELINEXOR

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  13. Selinexor

    Karyopharm Therapeutics Inc

    Carcinoma, Neuroendocrine

    phase 2 small molecule completed

    1 trial

  14. Selinexor

    Karyopharm Therapeutics Inc

    Primary Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  15. Selinexor

    Karyopharm Therapeutics Inc

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  16. Selinexor

    Karyopharm Therapeutics Inc

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  17. Selinexor

    Karyopharm Therapeutics Inc

    Relapse Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. Selinexor

    Karyopharm Therapeutics Inc

    Relapsed and Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Selinexor

    Karyopharm Therapeutics Inc

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  20. Selinexor

    Karyopharm Therapeutics Inc

    Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  21. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor Malignancy

    phase 2 small molecule terminated

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule active

    1 trial

  23. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    3 trials

  25. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

  26. Selinexor

    Karyopharm Therapeutics Inc

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  27. Selinexor

    Karyopharm Therapeutics Inc

    Coronavirus Infection

    phase 2 small molecule completed

    2 trials

  28. Selinexor

    Karyopharm Therapeutics Inc

    Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  29. Selinexor

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  30. Selinexor

    Karyopharm Therapeutics Inc

    Glioblastoma

    phase 2 small molecule terminated

    1 trial

  31. Selinexor

    Karyopharm Therapeutics Inc

    Glioblastoma Multiforme

    phase 2 small molecule terminated

    1 trial

  32. Selinexor

    Karyopharm Therapeutics Inc

    Leukemia

    phase 2 small molecule completed

    2 trials

  33. Selinexor

    Karyopharm Therapeutics Inc

    Locally Advanced Unresectable or Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  34. Selinexor

    Karyopharm Therapeutics Inc

    Metastatic Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  35. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma in Relapse

    phase 2 small molecule active

    1 trial

  36. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma, Refractory

    phase 2 small molecule active

    1 trial

  37. Selinexor

    Karyopharm Therapeutics Inc

    Myelodysplastic Syndrome

    phase 2 small molecule terminated

    1 trial

  38. Selinexor

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    2 trials

  39. Selinexor

    Karyopharm Therapeutics Inc

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  40. Selinexor

    Karyopharm Therapeutics Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  41. Selinexor

    Karyopharm Therapeutics Inc

    Ovarian Carcinoma

    phase 2 small molecule completed

    1 trial

  42. Selinexor

    Karyopharm Therapeutics Inc

    Peripheral T-cell Lymphoma (PTCL)

    phase 2 small molecule terminated

    1 trial

  43. Selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  44. Selinexor 100 mg

    Karyopharm Therapeutics Inc

    Non-Small Cell Lung Carcinoma (NSCLC)

    phase 2 small molecule completed

    1 trial

  45. Selinexor 20 MG Oral Tablet

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  46. Selinexor 60 MG

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule on hold

    1 trial

  47. Selinexor 60 mg

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  48. XPORT-MF-044

    Karyopharm Therapeutics Inc

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Karyopharm Therapeutics have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.